Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXACT-2 trial of endocardial XC001 gene therapy for refractory angina
2024-514874-36-01Phase 2Authorised
- Sponsor
- XyloCor Therapeutics
- Start
- Apr 2026
- Modality
- Gene Therapies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of encoberminogene rezmadenovec in refractory angina (RA) and coronary arteriosclerosis (2 arms), sponsored by XyloCor Therapeutics. Primary endpoint: Therapy response composite at Weeks 12 and 26. Planned start Apr 2026; status: authorised.
02
Drugs
encoberminogene rezmadenovec
03
Conditions
refractory angina (RA)coronary arteriosclerosis
Beyond the preview
Go deeper on 2024-514874-36-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514874-36-01.